SwineFarming.org

Home › Articles › Swine Breeding Deep Dives › PRRS-Resistant Genetics: The CD163 Deletion Story

Swine Breeding Deep Dives

PRRS-Resistant Genetics: The CD163 Deletion Story

PRRS is among the most costly swine diseases in the world, and decades of vaccination, biosecurity and eradication efforts have not eliminated it. Scientists therefore asked a different question: could the pig itself be made resistant? The answer centers on a protein called CD163 on the surface of certain immune cells, which the PRRS virus uses as its door into the cell. Removing the part of the protein the virus needs produces pigs that, in studies, do not become infected. This article tells that story and what it means for producers.

The disease problem

PRRS causes reproductive failure in sows and respiratory disease and poor growth in young pigs, and it spreads easily between herds. Producers lose money through abortions, stillbirths, weak piglets, mortality and slower growth. For background see PRRS in pigs and PRRS virus evolution, which explains why vaccines struggle to keep pace with changing strains. Because strains vary and mutate, a genetic approach that targets the host rather than the virus is attractive.

How the virus enters cells

The virus infects macrophages, immune cells found in the lungs and other tissues. It attaches to the cell surface and uses the CD163 protein to get inside and release its genetic material. Within CD163, one region, a domain known as SRCR5, appears to be especially important for infection. Researchers reasoned that if the pig lacked that region, the virus could not enter, and the pig might still function normally because CD163 has other roles.

The CD163 deletion

Using gene-editing tools, researchers produced pigs with a deletion in the part of the CD163 gene encoding the domain the virus uses. In published experiments such animals were exposed to PRRS viruses and did not become infected or sick, while normal pigs did. The edit removes a short stretch of DNA and does not add genes from another species. Detailed health monitoring found that the animals grew and reproduced normally under study conditions, though continuing evaluation is needed across lines and environments. See gene editing in pigs for the technology.

From research to commercial use

Moving from the lab to the market involves regulatory review, evidence that the animals are healthy and that the meat is safe, and approvals in export markets. A genetics company has pursued this pathway, and regulators in some countries have reviewed the application. Because decisions change, verify the present status of approvals in your country and in the countries that buy your pork. A technology that is cleared domestically but not by key importers can be hard to use. Also confirm when and how breeding stock will become available.

What resistant pigs would and would not do

BenefitLimit
Prevents infection by PRRS viruses that need CD163Does not protect against other diseases
Could cut production losses and reduce antibiotics for secondary infectionsDoes not remove the need for biosecurity
Works against many strains because it targets the hostThe virus might evolve if exposed
May reduce the chance of the herd spreading virusUnresistant neighbors still need protection

Resistant genetics would sit beside, not replace, tools described in PRRS eradication strategies and sow farm biosecurity.

Practical questions for a producer

  1. Will packers and export customers accept pigs from this line?
  2. How would resistant stock be introduced into my herd, and at what cost?
  3. How does the line perform on growth, litter size and longevity compared with my current genetics? See maternal line selection.
  4. Do I need to keep other PRRS controls in place during the transition?
  5. How will mixed herds, with resistant and normal pigs, be managed?

A resistant sow farm can still be exposed to virus from outside; the point is that infection should not establish in the animals.

Risks, ethics and the road ahead

Concerns include the possibility of viral evolution, effects on other aspects of immunity, public acceptance and concentration of genetic ownership in a few companies. CD163 plays roles beyond PRRS, so long-term welfare monitoring matters. On the other side, preventing a disease that kills piglets and causes suffering has a strong welfare argument. The coming years will show how quickly resistant pigs spread. For national and market data, see sources such as USDA APHIS swine health and the National Pork Board.

Lessons from the PRRS story for other diseases

The CD163 work shows a pattern that could apply to other pathogens that depend on a host receptor. Identify the receptor, test whether the pig can live without the part the virus uses, confirm the animal stays healthy, then pursue approvals. African swine fever and other diseases lack such a clear single entry point, so progress there is harder. Genetic resistance also needs to be paired with surveillance, since a disease that disappears from one herd can return through contact with unprotected animals. Producers should treat resistant genetics as one layer of protection, keep vaccination and testing programs under veterinary guidance, and plan for the possibility that viruses change over time.

What a transition might look like

If resistant stock becomes available, most farms will not swap overnight. A multiplier or nucleus herd would likely convert first, supplying gilts and semen to commercial farms over several years. Producers would need to decide whether to bring in resistant gilts alongside existing sows, how to track both groups, and when to reduce PRRS-specific costs such as vaccination and herd closure. A phased approach with clear records, as in gilt acclimation programs, reduces risk.

FAQ

Are PRRS-resistant pigs genetically modified?

They are gene-edited, with a small deletion in a pig gene and no foreign DNA. How regulators classify them differs by country.

Can they still get other diseases?

Yes. The edit targets only the PRRS entry route, so other disease control remains essential.

When will producers be able to buy them?

That depends on regulatory and export approvals, so ask your genetics supplier and check official sources.

Keep learning

Browse all 700 guides →